NCT06258122

Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

Evolution Over 15 Years (2008-2023) of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
HIV Infections
Study type
Observational
Sponsor & location
Primary sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Timeline & enrollment
Phase
N/A
Start date
Mar 15, 2024
End date
Mar 15, 2025
Enrollment
120 participants
Primary outcome

measure of the frequency of circulating leukocyte cells,measure the number of hematopoietic stem cells in peripheral blood and their ability to develop a myeloid or lymphoid lineage in culture

Summary

Main objective is:
 
 - To characterize the evolution of the immuno-virological profile of circulating blood
 cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008
 
 - To evaluate the role of immune aging and inflammatory profile in the occurrence of
 comorbidities in HIV-infected individuals over a 15-year period
 
 The alterations that affect the innate and adaptive immune cell compartments in HIV-infected
 patients are reminiscent of the process of immune aging, characteristic of old age. These
 alterations, the presumed cause of which is the chronic systemic immune activation
 established in patients, contribute to the depletion of lymphoid resources which probably
 leads to the decline of immune competence with the progression of HIV disease.
 
 The comparison between HIV-1-infected patients and uninfected older adults goes beyond the
 mere appearance of immunosenescence and extends to the deterioration of a number of
 physiological functions linked to inflammation and to systemic aging.
 
 By inducing persistent and lasting immune activation, HIV-1 infection is now considered a
 model of accelerated immunosenescence and systemic aging. During this process, the immune
 system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be
 eliminated.
 
 To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose
 an extensive immune and virological evaluation in patients who participated in a
 cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of
 evolution in order to determine their immune and viral trajectories, to compare these
 trajectories with the major clinical events and the comorbidities occurring in them.

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06258122
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06258122 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.